Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06570473). This is a study registration, not published results. Lead sponsor: University of Alberta. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 30 participants (ESTIMATED). Conditions: Pulmonary Hypertension, Right Ventricular Dysfunction, Right Heart Failure. Interventions: DRUG: Empagliflozin; DRUG: Ranolazine. Primary outcome measures: The proportion of eligible participants approached that consent , 16 weeks; The proportion of participants who consent that are randomized , 16 weeks; Average enrolment rate of participants per centre per month , 16 weeks; Loss of follow up or death , 16 weeks; Ability to capture data for secondary outcomes , 16 weeks. Brief summary: The primary objective of the CRAVE feasibility trial is to assess the feasibility of conducting a larger CRAVE platform trial by performing a randomized trial of 30 participants with pulmonary hypertension and right ventricular dysfunction, comparing empagliflozin or ranolazine plus standard of care to standard of care alone.